Age- and sex-specific reference intervals for the serum cystatin C/creatinine ratio in healthy children (0–18 years old)

Liu, Changjin; Wen, Jing; Xiang, Jialin; Ouyang, Xuhong; Yang, Yan; Lu, Wei; Wang, Jianwei; Huang, Jian; Min, Xun

doi:10.1177/0300060519855575

Cited by 11 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study found that boys had higher cystatin C levels than girls, which was consistent with other findings that boys had higher cystatin C levels than girls after 1 year of age (20). The possible reason for the result might be that adolescent boys had a higher increase in muscle mass than girls (20). In addition, renal factors, hormonal factors, or other factors interfering with the determination of the cystatin C level in individual girls might also explain sex-related differences (21).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14–17 Years

et al. 2022

View full text Add to dashboard Cite

BackgroundThe association between serum cystatin C levels and obesity has not been fully explored in adolescents. This study aimed to explore the association between serum cystatin C levels and obesity in adolescents of different sexes.MethodsWe conducted a cross-sectional study including 481 adolescents aged 14−17 years. Cystatin C level was measured by immunoassay. Health examinations data, biochemical parameters, and questionnaire information were collected. The restricted cubic spline model analyzed the association between cystatin C levels and obesity in boys and girls.ResultsBoys exhibited significantly higher cystatin C levels than girls, with a mean level of 0.97 ± 0.10 mg/L in boys and 0.86 ± 0.09 mg/L in girls (P < 0.001). The restricted cubic spline model suggested that low or high cystatin C levels were associated with an increased risk of obesity in boys, whereas only higher cystatin C levels were associated with an increased risk of obesity in girls.ConclusionsA U-shaped correlation was observed between serum cystatin C levels and the risk of obesity in boys. However, in girls, the risk of obesity showed a trend of initially increase and then decrease with increasing cystatin C levels. Longitudinal studies should be conducted to further investigate the diagnostic potential of cystatin C in the progression of early obesity in adolescents of different sexes.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 90%

Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14–17 Years

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover, we observed that Cre/CysC ratio was positively associated with eGFRcys and negatively associated with age and BFP, as was shown in previous reports. ( 13 , 34 , 35 ) Namely, loss of muscle mass evaluated with SMI was associated with aging, renal dysfunction, and obesity. These factors exactly matched the factors responsible for sarcopenia, which involves multifactorial processes, including aging- and disease-related sarcopenia, and sarcopenic obesity.…”

Section: Discussionmentioning

confidence: 99%

Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project

Mikami

Endo

Sawada

et al. 2022

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

We evaluated the feasibility of using serum creatinine-to-cystatin C ratio in the assessments of muscle mass and strength in nonalcoholic fatty liver disease. In a community-based crosssectional study, skeletal muscle mass and handgrip strength were assessed in 641 Japanese adults. Low skeletal muscle mass index and low handgrip strength were defined as indicated in the sarcopenia diagnostic criteria of the Japan Society of Hepatology. Nonalcoholic fatty liver disease was defined as fatty liver on ultrasonography in the absence of other causes of steatosis. The creatinine-to-cystatin C ratio was useful for identifying the participants with low skeletal muscle mass index, with an area under the receiver-operating characteristic curve of 0.84 [95% confidence interval (CI), 0.77-0.91] in men and 0.72 in women (95% CI, 0.65-0.78), and those with low handgrip strength, with an area under the receiver-operating characteristic curve of 0.96 (95% CI, 0.93-0.99) in men and 0.79 (95% CI, 0.66-0.92) in women. Moreover, the creatinine-to-cystatin C ratio correlated with skeletal muscle mass index (r = 0.511, p<0.001) and handgrip strength (r = 0.657, p<0.001), whereas it did not correlate with exacerbation of hepatic steatosis. In this study, creatinine-tocystatin C ratio correlated with muscle mass and strength in nonalcoholic fatty liver disease regardless of hepatic steatosis.

show abstract

“…Exclusion criteria included treatment with PZT for an indication other than a CF exacerbation, requirement of a vasopressor, or baseline SCr above age-adjusted normal. 18 Patients were divided into two groups based on PZT infusion time: over 30 min (TI group) or 4 h (EI group). Baseline demographic data and clinical data, PZT dosing information, and CF comorbidities (i.e., CF-related diabetes, CF-related liver disease, and hypochloronatremia) were extracted from medical records of eligible patients.…”

Section: Study Design and Populationmentioning

confidence: 99%

Evaluation of the safety of piperacillin‐tazobactam extended infusion in pediatric cystic fibrosis patients

Riggsbee

Engdahl

Pettit

2023

Pediatric Pulmonology

View full text Add to dashboard Cite

Background Patients with cystic fibrosis (CF) may be treated with piperacillin‐tazobactam (PZT) for acute pulmonary exacerbations. Extending the infusion of PZT is one strategy to increase efficacy. Direct comparison, with respect to the incidence of acute kidney injury (AKI), between these two strategies has not been evaluated in pediatric patients with CF. The primary objective of this study was to compare the incidence of AKI in pediatric CF patients receiving extended infusion (EI) PZT versus traditional infusion (TI). Methods This IRB‐approved, retrospective analysis included patients ages 30 days to 18 years that received PZT for at least 48 h between January 1, 2008, and January 1, 2020. PZT was infused over 30 min (TI group) or 4 h (EI group). Results Two hundred and four patients were included (TI: 109, EI: 95). Median age was 8 years (4–13) and 7 years (3–12) in the TI and EI groups (p = 0.15). The groups did not differ significantly in their baseline characteristics. There were 12 (11%) AKIs in the TI group and 8 (8.4%) in the EI group (p = 0.53). There was one occurrence of serum sickness in the TI group and none in the EI group. The incidence of thrombocytopenia was similar between the two groups. Median treatment duration was 8 days (5–11) and 9 days (5–13) for the TI and EI groups, respectively (p = 0.24). Conclusions There was no significant increase in AKI in pediatric patients with CF receiving PZT by EI compared with TI. EI may be utilized to optimize the pharmacokinetics of PZT in pediatric CF patients.

show abstract

Age- and sex-specific reference intervals for the serum cystatin C/creatinine ratio in healthy children (0–18 years old)

Cited by 11 publications

References 28 publications

Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14–17 Years

Serum Cystatin C Levels Are Associated With Obesity in Adolescents Aged 14–17 Years

Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project

Evaluation of the safety of piperacillin‐tazobactam extended infusion in pediatric cystic fibrosis patients

Contact Info

Product

Resources

About